Breaking News

Novartis Halts COVID-19 HCQ Study

Discontinues hydroxychloroquine clinical trial based on slow enrollment, no safety issues have been reported or efficacy conclusions made.

By: Contract Pharma

Contract Pharma Staff

Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made trial completion infeasible.   The Swiss pharma giant said recruitment challenge facing the HCQ trial wouldn’t allow its clinical team to be able to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with COVID-19.   No safety issues have been reported, and there are no conclusions on effic...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters